Treatment of Anal Canal Cancer: Limitations of Chemotherapy and Radiotherapy
Author Information
Author(s): Chauveinc L, Buthaud X, Falcou M C, Mosseri V, De la Rochefordière A, Pierga J Y, Girodet J, Salmon R J
Primary Institution: Institut Curie
Hypothesis
What are the criteria for prescribing concurrent chemotherapy and radiotherapy for anal canal cancer?
Conclusion
The study found that older patients and those with smaller tumors were less likely to receive concurrent chemotherapy and radiotherapy, despite the treatment being considered the gold standard.
Supporting Evidence
- 43.3% of patients received concurrent chemotherapy and radiotherapy.
- 66% overall 4-year survival rate was observed.
- Complications were more frequent in patients receiving concurrent chemotherapy.
Takeaway
Doctors usually give a special treatment for anal cancer, but they often skip it for older people or those with smaller tumors, even if it might help.
Methodology
The study analyzed treatment outcomes for 67 patients with anal canal cancer treated with either concurrent chemotherapy and radiotherapy or radiotherapy alone.
Potential Biases
Potential bias due to the retrospective nature of the study and the exclusion of certain patient groups.
Limitations
The study only included patients treated at one institution and may not be generalizable to all populations.
Participant Demographics
Mean age was 65 years, with a sex ratio of nine women to one man.
Statistical Information
P-Value
p<0.001
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website